Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 278

1.

Tumor tissue protein signatures reflect histological grade of breast cancer.

Skoog P, Ohlsson M, Fernö M, Rydén L, Borrebaeck CAK, Wingren C.

PLoS One. 2017 Jun 26;12(6):e0179775. doi: 10.1371/journal.pone.0179775. eCollection 2017.

2.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Zucht HD, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.

Oncotarget. 2017 Apr 24. doi: 10.18632/oncotarget.17397. [Epub ahead of print] Review.

3.

Evaluation of the GARD assay in a blind Cosmetics Europe study.

Johansson H, Gradin R, Forreryd A, Agemark M, Zeller K, Johansson A, Larne O, van Vliet E, Borrebaeck C, Lindstedt M.

ALTEX. 2017 Feb 17. doi: 10.14573/altex.1701121. [Epub ahead of print]

4.

Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.

Borrebaeck CA.

Nat Rev Cancer. 2017 Mar;17(3):199-204. doi: 10.1038/nrc.2016.153. Epub 2017 Feb 3. Review.

PMID:
28154374
5.

Testing Human Skin and Respiratory Sensitizers-What Is Good Enough?

Malmborg A, Borrebaeck CA.

Int J Mol Sci. 2017 Jan 24;18(2). pii: E241. doi: 10.3390/ijms18020241. Review.

6.

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C.

Blood Cancer J. 2016 Nov 18;6(11):e501. doi: 10.1038/bcj.2016.113. No abstract available.

7.

Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity.

Delfani P, Sturfelt G, Gullstrand B, Carlsson A, Kassandra M, Borrebaeck CA, Bengtsson AA, Wingren C.

Lupus. 2017 Apr;26(4):373-387. doi: 10.1177/0961203316669240. Epub 2016 Sep 30.

PMID:
27694630
8.

Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays.

Gerdtsson AS, Dexlin-Mellby L, Delfani P, Berglund E, Borrebaeck CA, Wingren C.

Microarrays (Basel). 2016 Jun 8;5(2). pii: E16. doi: 10.3390/microarrays5020016.

9.

Generation and analyses of human synthetic antibody libraries and their application for protein microarrays.

Säll A, Walle M, Wingren C, Müller S, Nyman T, Vala A, Ohlin M, Borrebaeck CAK, Persson H.

Protein Eng Des Sel. 2016 Oct;29(10):427-437. doi: 10.1093/protein/gzw042. Epub 2016 Sep 1.

PMID:
27590051
10.

Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.

Gerdtsson AS, Wingren C, Persson H, Delfani P, Nordström M, Ren H, Wen X, Ringdahl U, Borrebaeck CA, Hao J.

Mol Oncol. 2016 Oct;10(8):1305-16. doi: 10.1016/j.molonc.2016.07.001. Epub 2016 Jul 12.

11.

Animal-based antibodies: Obsolete.

Gray AC, Sidhu SS, Chandrasekera PC, Hendriksen CF, Borrebaeck CA.

Science. 2016 Jul 29;353(6298):452-3. doi: 10.1126/science.aag3305. No abstract available.

PMID:
27471297
12.

Animal-Friendly Affinity Reagents: Replacing the Needless in the Haystack.

Gray AC, Sidhu SS, Chandrasekera PC, Hendriksen CF, Borrebaeck CA.

Trends Biotechnol. 2016 Dec;34(12):960-969. doi: 10.1016/j.tibtech.2016.05.017. Epub 2016 Jul 20. Review.

13.

Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.

Delfani P, Dexlin Mellby L, Nordström M, Holmér A, Ohlsson M, Borrebaeck CA, Wingren C.

PLoS One. 2016 Jul 14;11(7):e0159138. doi: 10.1371/journal.pone.0159138. eCollection 2016.

14.

Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach.

Säll A, Persson H, Ohlin M, Borrebaeck CA, Wingren C.

N Biotechnol. 2016 Sep 25;33(5 Pt A):503-13. doi: 10.1016/j.nbt.2015.12.001. Epub 2015 Dec 15.

15.

A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.

Gerdtsson AS, Malats N, Säll A, Real FX, Porta M, Skoog P, Persson H, Wingren C, Borrebaeck CA.

Int J Proteomics. 2015;2015:587250. doi: 10.1155/2015/587250. Epub 2015 Oct 26.

16.

Advanced technologies and diagnostic spin-outs: an interview with Carl Borrebaeck.

Borrebaeck C.

Expert Rev Mol Diagn. 2015;15(11):1409-10. doi: 10.1586/14737159.2015.1100499. Epub 2015 Oct 14.

PMID:
26465682
17.

Prediction of chemical respiratory sensitizers using GARD, a novel in vitro assay based on a genomic biomarker signature.

Forreryd A, Johansson H, Albrekt AS, Borrebaeck CA, Lindstedt M.

PLoS One. 2015 Mar 11;10(3):e0118808. doi: 10.1371/journal.pone.0118808. eCollection 2015.

18.

Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.

Ko BK, Lee SY, Lee YH, Hwang IS, Persson H, Rockberg J, Borrebaeck C, Park D, Kim KT, Uhlen M, Lee JS.

Mol Oncol. 2015 Feb;9(2):398-408. doi: 10.1016/j.molonc.2014.09.007. Epub 2014 Sep 28.

19.

Identification of plasma protein profiles associated with risk groups of prostate cancer patients.

Nordström M, Wingren C, Rose C, Bjartell A, Becker C, Lilja H, Borrebaeck CA.

Proteomics Clin Appl. 2014 Dec;8(11-12):951-62. doi: 10.1002/prca.201300059. Epub 2014 Oct 22.

20.

Molecular design of recombinant scFv antibodies for site-specific photocoupling to β-cyclodextrin in solution and onto solid support.

Petersson L, Städe LW, Brofelth M, Gärtner S, Fors E, Sandgren M, Vallkil J, Olsson N, Larsen KL, Borrebaeck CA, Duroux L, Wingren C.

Biochim Biophys Acta. 2014 Dec;1844(12):2164-73. doi: 10.1016/j.bbapap.2014.08.010. Epub 2014 Aug 27.

Supplemental Content

Loading ...
Support Center